The 13 most recent market catalysts affecting $ARTL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
Artelo Biosciences shares are trading higher after the company announced the filing of a provisional patent application for ART27.13 as a monotherapy and in combination with GLP-1 receptor agonists.
This news is a significant positive catalyst for Artelo Biosciences (ARTL) as it expands the potential market and therapeutic applications for their drug candidate ART27.13. The fi…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 75
Arteris shares are trading higher after Craig-Hallum initiated coverage on the stock with a Buy rating and announced a $30 price target.
This headline represents a significant corporate catalyst for Arteris (ARTL). Analyst initiation with a 'Buy' rating and a specific price target often acts as a strong endorsement,…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug
Artelo Biosciences (ARTL) announced compelling nonclinical data for its drug ART27.13, demonstrating that it achieved weight loss comparable to semaglutide alone and doubled weight…
Sep 16, 2026
Corporate Catalyst
Bearish
Impact 85
Artelo Biosciences shares are trading lower. The company reported nonclinical results showing its oral cannabinoid agonist ART27.13 cut body weight by about 20% in obese mice, matching semaglutide.
The headline presents a classic 'buy the rumor, sell the news' scenario or investor skepticism regarding early-stage nonclinical data. While the results are promising for ART27.13,…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
Artelo Biosciences Says ART27.13 Cut Body Weight About 20% In Obese Mice, Matching Semaglutide; Combination With Semaglutide Produced About 40% Weight Loss
This news is a significant corporate catalyst for Artelo Biosciences, as positive preclinical data for ART27.13, especially its comparable efficacy to semaglutide and synergistic p…
Aug 27, 2026
Corporate Catalyst
Bearish
Impact 85
Artelo Biosciences shares are trading lower after the company announced a 1-for-9 reverse stock split.
A reverse stock split is a corporate action where a company reduces the number of its outstanding shares, increasing the par value per share proportionally. While it doesn't change…
Aug 27, 2026
Corporate Catalyst
Neutral
Impact 60
Artelo Biosciences Announces 1-For-9 Reverse Stock Split, Effective August 31
Artelo Biosciences is implementing a 1-for-9 reverse stock split, effective August 31, 2026. This action is primarily taken to increase the per-share price of their common stock, w…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 65
Artelo Biosciences Issued Notification Of Allowance From Japanese Patent Office With Decision To Grant Patent Application For Commercial Formulation Of ART27.13
Artelo Biosciences has secured a patent allowance from the Japanese Patent Office for the commercial formulation of ART27.13, a drug currently undergoing Phase 2 clinical trials. T…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 65
Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies
Artelo Biosciences received a Notice of Allowance from the USPTO for a patent covering the intended commercial formulation of ART27.13, a peripherally selective cannabinoid agonist…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY
Artelo Biosciences (ARTL) announced a dramatic improvement in its Q2 earnings per share, with losses shrinking from $(16.83) to $(0.89) year-over-year. This 94.71% reduction in los…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 65
Artelo Biosciences Says First Patient Dosed In DREAM Study Evaluating Effects Of ART27.13 In Patients With Glaucoma Or Ocular Hypertension; Initial DREAM Study Results Anticipated In Q4
Artelo Biosciences has dosed the first patient in its DREAM study for ART27.13, a synthetic cannabinoid, to treat glaucoma and ocular hypertension. This is significant as it expand…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 65
Artelo Biosciences Announces Oral Administration Of ART26.12 Lowers Osteoarthritis-Associated Pain Behaviors Over 4-Week Testing; Shows Efficacy To Naproxen
Artelo Biosciences reported positive nonclinical results for its drug candidate ART26.12, demonstrating efficacy in reducing osteoarthritis pain comparable to naproxen, a widely us…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Artelo Biosciences Reports Preclinical Results For ART27.13 in Cancer-Related Neuropathic Pain; Findings Suggest Broader Utility In Cancer Supportive Care, Building On Interim Findings From CAReS Phase 2 Clinical Study Which Demonstrated Improvements In Body Weight, Lean Body Mass And Activity Levels
Artelo Biosciences (ARTL) reported promising preclinical results for ART27.13, demonstrating its ability to reduce neuropathic pain in a model of paclitaxel-induced peripheral neur…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.